Honasa buys Fluence: ₹135cr nutraceutical push in 2026

Deal snapshot: what Honasa has agreed to buy

Honasa Consumer Ltd, the parent of Mamaearth, has approved the acquisition of a majority stake in Mumbai-based Fluence Pharma, marking its entry into nutraceuticals. The company will acquire a 58% equity stake in Fluence at an enterprise value of about ₹135 crore, subject to closing adjustments and completion of conditions precedent. The transaction is structured entirely as a secondary share purchase, as per the company filing cited in the report. Honasa plans to acquire the remaining 42% in two tranches over the next 5 to 7 years from completion of the initial acquisition. The deal is expected to close within the next eight weeks, according to the filing. Post-acquisition, Fluence is expected to work with Honasa Health, a newly incorporated subsidiary. Honasa said the acquisition reflects its push into science-led wellness and “inside-out” beauty solutions.

Why a beauty company is moving toward supplements

Industry executives told Mint that India’s beauty and personal care (BPC) brands are increasingly looking to healthcare and prescription-led segments to build consumer trust and open new growth avenues. In this context, Honasa’s move is being positioned as more than just a category extension from topical products into pills and powders. The company is attempting to blur the lines between cosmetics, wellness, and healthcare as consumer preferences shift toward holistic routines. The reports describe nutraceuticals as a new battleground for differentiation, particularly for digital-first BPC companies that already rely on strong consumer engagement. Honasa’s rationale is anchored in the idea that beauty concerns are increasingly being addressed “at the root,” not only through topical actives. Varun Alagh, co-founder and CEO of Honasa Consumer, said the next decade would be defined by the convergence of science-backed skin and hair care with nutraceuticals.

Fluence Pharma: brands and positioning

Fluence Pharma is described as a science-backed nutraceuticals player with condition-specific OTC supplements. Its portfolio includes products under brands such as Hair Fact, Skin Fact, and Pro Fact. Honasa also pointed to Fluence’s patented clinical science and practitioner trust as key strengths that it wants to scale using its own capabilities. Another report highlighted Fluence’s dermatologist-led distribution network and “Cyclical Nutrition Therapy” as factors behind Honasa’s decision. The strategic fit, as described, is a combination of clinical credibility and wider consumer reach. Several reports frame Fluence as operating in structured hair treatment and science-backed beauty wellness segments. Honasa’s plan is to bring this into a business-to-consumer framework under its own umbrella.

Honasa Health: the new vehicle for nutraceuticals

Alongside the acquisition, Honasa is setting up a wholly-owned subsidiary called Honasa Health to build a consumer nutraceuticals franchise. The company said Honasa Health will scale a differentiated B2C nutrition portfolio by combining Fluence’s clinical science and practitioner trust with Honasa’s brand building, consumer insights, and digital-first distribution. The new subsidiary is also described as being led by CEO Dheeraj Nagpal. Structurally, the creation of a separate entity signals that the nutraceuticals business will be managed as a focused vertical rather than as a small line extension. The reports emphasise that Honasa is not becoming a pharmaceutical company, but extending its BPC portfolio into supplements positioned around hair and skin health. The goal, as stated, is to serve the broader wellness journey of the consumer.

Consolidation trend in India’s BPC market

The acquisition is described as Honasa’s second deal in under a year, and Fluence will become the ninth brand under Honasa’s umbrella. Coverage around the deal highlights a broader consolidation trend, where established consumer platforms acquire science-led or clinically positioned brands to expand consumer lifetime value. Another report also linked the move to the wider shift in India’s beauty market toward ingredients and supplements, mentioning that science-led beauty brands are attracting interest. The underlying argument is that consumers are increasingly responding to claims supported by clinical positioning and practitioner networks. For larger platforms, acquisitions can provide faster access to credibility, specialised products, and a pipeline that can be expanded via marketing and distribution.

Market sizing cues and growth targets cited

One report described India’s ‘beauty-from-within’ segment as being valued at more than ₹16,000 crore, positioning nutraceuticals as a meaningful adjacency for beauty companies. Separately, commentary from an analyst interaction cited that Honasa had identified nutraceuticals among its “next horizon” categories, alongside fragrance and oral care. The same commentary said these horizon categories are targeted to deliver revenue of almost ₹250 crore in the next five years. While that number was presented as a target across multiple categories, it helps contextualise why the company is investing in new verticals. Industry sources in another report estimated the deal value at $15-18 million, though the company disclosure focused on the ₹135 crore enterprise value.

Key facts table

Market impact: what changes for consumers and investors

For consumers, the reported strategy is to connect topical skin and hair care with supplements that claim to support outcomes from within, particularly in hair and skin categories. For Honasa, the key operational shift is building a B2C nutraceuticals franchise using a clinically positioned product base and a practitioner-led network, amplified by digital-first distribution. Investors will likely track how quickly the company can close the transaction, integrate the brand, and scale the portfolio without diluting its existing BPC focus. The deal structure also spreads the full buyout over 5 to 7 years, which can help manage integration risk and capital allocation. Because the purchase is described as entirely secondary, the transaction mechanics are tied to stake transfers rather than infusion into the target, based on the filing referenced. The creation of Honasa Health provides a clearer reporting and execution lens for this new category.

Why this matters: the “inside-out” thesis becomes a strategy

Across the reports, the consistent theme is that beauty, wellness, and nutrition are converging, and BPC companies are responding by adding science-backed supplement offerings. The stated rationale is that trust in outcomes is increasingly linked to clinical science, condition-specific positioning, and practitioner endorsement. Honasa’s acquisition of Fluence is being framed as a way to import those attributes, then scale them using brand building and digital distribution. The move also highlights how competitive differentiation in BPC is shifting from purely product launches to capability-building, including acquisitions. If the nutraceuticals segment continues to grow as described, brands with cross-category credibility may have an advantage in retaining consumers across longer “beauty and wellness” journeys.

What to watch next

The immediate milestone is closing of the 58% acquisition, which the filing says is expected within eight weeks. Next, the market will watch how Honasa Health is operationalised, and how Fluence’s products are expanded within a direct-to-consumer playbook while retaining practitioner trust. Over a longer horizon, Honasa’s phased purchase of the remaining 42% over 5 to 7 years will be a key indicator of performance-linked confidence and integration progress. Any additional disclosures around portfolio expansion under Honasa Health and execution timelines are likely to shape how this strategy is evaluated.